Shares in Northwest Biotherapeutics (NASDAQ:NWBO), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, have jumped 12% pre-market after the company said the Data Safety Monitoring Board has recommended its Phase III trial into a lethal form of brain cancer continue. The company’s lead program is a 312-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). Northwest Biotherapeutics (NASDAQ:NWBO)’s stock on March 6, 2014 was down 10.24% closing at $5.96. Its fifty two week range is $2.98 – $20.00. The company’s total market capitalization stands at $229.5 million. The total volume in the last trading session reached 1.9 million compared to it’s average volume of around 140 thousand shares. Northwest Biotherapeutics (NASDAQ:NWBO) has a one year target estimate of 7.67

FBR Capital believes yesterday’s sell-off in shares of Children’s Place (NASDAQ:PLCE) presents an even more attractive entry point into the name, according to TheFlyOnTheWall.com. The firm believes the company’s fundamentals margin improvement story remains intact and reiterates an Outperform rating on the stock with a $60 price target. Children’s Place (NASDAQ:PLCE)’s stock on March 6, 2014 closesd at $50.66. Its fifty two week range is $43.01 – $58.89. The company’s total market capitalization stands at $1.13 billion. The company has average volume of around 435 thousand shares. Children’s Place (NASDAQ:PLCE) has a one year target estimate of 58.06.

Baird raised its price target on Cooper Companies (NYSE:COO) following Q1 results. The firm sees an acceleration of the contact lens end market, sustainable CVI organic revenue growth, and margin expansion opportunities. Shares are Outperform rated. Cooper Companies (NYSE:COO)’s stock on March 6, 2014 closesd at $130.09. Its fifty two week range is $102.72 – 135.41. The company’s total market capitalization stands at $6.24 billion. The company has average volume of around 527 thousand shares. Cooper Companies (NYSE:COO) has a one year target estimate of $138.11.

Baird believes investors should scale into positions of Verisk Analytics (NASDAQ:VRSK) rather than aggressively purchase shares following its annual investor day, according to TheFlyOnTheWall.com. The firm remains confident the company will be able to generate above average returns in any probable economic environment but makes its recommendation due to current valuation. Shares are Outperform rated with a $74 price target. Verisk Analytics (NASDAQ:VRSK)’s stock on March 6, 2014 closesd at $62.58. Its fifty two week range is $54.68 – 69.09. The company’s total market capitalization stands at $10.44 billion. The company has average volume of around 832 thousand shares. Verisk Analytics (NASDAQ:VRSK) has a one year target estimate of $70.69.